Market Closed -
Nasdaq
04:30:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
0.9
USD
|
+2.49%
|
|
+4.29%
|
-13.88%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Capitalization
1 |
5.327
|
17.09
|
14.72
|
12.94
|
16.54
|
14.26
|
-
|
Enterprise Value (EV)
1 |
5.327
|
59.7
|
23.05
|
19.96
|
0.2314
|
-2.037
|
-3.937
|
P/E ratio
|
-1.02
x
|
-1.57
x
|
-2.66
x
|
-1.74
x
|
0.71
x
|
-7.5
x
|
-12.9
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
0.05
x
|
0.22
x
|
0.14
x
|
0.12
x
|
0.36
x
|
0.28
x
|
0.22
x
|
EV / Revenue
|
0.05
x
|
0.76
x
|
0.22
x
|
0.18
x
|
0.01
x
|
-0.04
x
|
-0.06
x
|
EV / EBITDA
|
0.69
x
|
-93.1
x
|
-6.68
x
|
3.32
x
|
-1.31
x
|
-1.63
x
|
-1.04
x
|
EV / FCF
|
-
|
-9.26
x
|
-3.18
x
|
-3.96
x
|
0.12
x
|
-1.02
x
|
-1.01
x
|
FCF Yield
|
-
|
-10.8%
|
-31.4%
|
-25.3%
|
864%
|
-98.2%
|
-99.1%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
2,049
|
4,760
|
5,771
|
15,139
|
15,826
|
15,848
|
-
|
Reference price
2 |
2.600
|
3.590
|
2.550
|
0.8549
|
1.045
|
0.9000
|
0.9000
|
Announcement Date
|
3/6/20
|
3/9/21
|
3/22/22
|
3/15/23
|
3/22/24
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net sales
1 |
114.2
|
78.16
|
106.6
|
112.2
|
45.78
|
51.55
|
63.4
|
EBITDA
1 |
7.703
|
-0.641
|
-3.448
|
6.01
|
-0.176
|
1.25
|
3.8
|
EBIT
1 |
-3.596
|
-7.208
|
-11.6
|
-3.105
|
-4.346
|
-1.31
|
1.1
|
Operating Margin
|
-3.15%
|
-9.22%
|
-10.88%
|
-2.77%
|
-9.49%
|
-2.54%
|
1.74%
|
Earnings before Tax (EBT)
1 |
-5.268
|
-5.156
|
-8.871
|
-5.078
|
-2.521
|
-1.16
|
1.4
|
Net income
1 |
-5.223
|
-8.373
|
-4.889
|
-7.168
|
23.22
|
-1.9
|
-1.1
|
Net margin
|
-4.57%
|
-10.71%
|
-4.59%
|
-6.39%
|
50.71%
|
-3.69%
|
-1.74%
|
EPS
2 |
-2.560
|
-2.280
|
-0.9600
|
-0.4900
|
1.470
|
-0.1200
|
-0.0700
|
Free Cash Flow
1 |
-
|
-6.446
|
-7.238
|
-5.046
|
2
|
2
|
3.9
|
FCF margin
|
-
|
-8.25%
|
-6.79%
|
-4.5%
|
4.37%
|
3.88%
|
6.15%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
160%
|
102.63%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
8.61%
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/6/20
|
3/9/21
|
3/22/22
|
3/15/23
|
3/22/24
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
28.86
|
29.54
|
25.05
|
30.72
|
24.24
|
32.14
|
25.7
|
8.893
|
10.44
|
14.11
|
10.25
|
12.5
|
13.9
|
14.9
|
12.5
|
EBITDA
1 |
-0.639
|
1.019
|
0.128
|
1.276
|
-0.614
|
3.108
|
1.653
|
-0.802
|
-1.092
|
-0.126
|
-0.6
|
-0.2
|
0.9
|
3.3
|
0.1
|
EBIT
1 |
-1.884
|
-3.633
|
-2.555
|
-1.198
|
-1.491
|
2.139
|
0.73
|
-2.036
|
-1.661
|
-0.801
|
-1.235
|
-0.595
|
0.095
|
0.875
|
-0.6
|
Operating Margin
|
-6.53%
|
-12.3%
|
-10.2%
|
-3.9%
|
-6.15%
|
6.66%
|
2.84%
|
-22.89%
|
-15.92%
|
-5.68%
|
-12.05%
|
-4.76%
|
0.68%
|
5.87%
|
-4.8%
|
Earnings before Tax (EBT)
1 |
-2.141
|
-4.385
|
-2.751
|
-1.903
|
-2.251
|
1.827
|
0.435
|
-1.305
|
-2.365
|
0.961
|
-1.185
|
-0.545
|
0.145
|
0.925
|
-0.5
|
Net income
1 |
-2.62
|
-4.887
|
-4.18
|
-2.055
|
-2.363
|
1.43
|
-0.044
|
25.11
|
-3.101
|
1.249
|
-1.8
|
-1.3
|
-0.3
|
1.5
|
-1
|
Net margin
|
-9.08%
|
-16.54%
|
-16.69%
|
-6.69%
|
-9.75%
|
4.45%
|
-0.17%
|
282.38%
|
-29.72%
|
8.85%
|
-17.56%
|
-10.4%
|
-2.16%
|
10.07%
|
-8%
|
EPS
2 |
-0.5100
|
-0.9300
|
-0.3300
|
-0.1300
|
-0.1500
|
0.1000
|
-0.002800
|
1.590
|
-0.2000
|
0.0800
|
-0.1100
|
-0.0800
|
-0.0200
|
0.1000
|
-0.0600
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/12/21
|
3/22/22
|
5/23/22
|
8/12/22
|
11/14/22
|
3/15/23
|
5/15/23
|
8/11/23
|
11/8/23
|
3/22/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net Debt
1 |
-
|
42.6
|
8.33
|
7.02
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
16.3
|
16.3
|
18.2
|
Leverage (Debt/EBITDA)
|
-
|
-66.47
x
|
-2.416
x
|
1.168
x
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-6.45
|
-7.24
|
-5.05
|
2
|
2
|
3.9
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
1.49
|
0.79
|
1.19
|
0.7
|
0.8
|
0.9
|
Capex / Sales
|
-
|
1.91%
|
0.74%
|
1.06%
|
1.52%
|
1.55%
|
1.42%
|
Announcement Date
|
3/6/20
|
3/9/21
|
3/22/22
|
3/15/23
|
3/22/24
|
-
|
-
|
Average target price
5
USD Spread / Average Target +455.56% Consensus |
1st Jan change
|
Capi.
|
---|
| -13.88% | 14.26M | | -17.89% | 8.25B | | +39.20% | 3.58B | | -39.11% | 2.46B | | -8.06% | 2.46B | | -7.35% | 2.38B | | -12.61% | 1.81B | | -19.01% | 1.55B | | -40.66% | 1.21B | | +7.56% | 1.11B |
Medical & Diagnostic Laboratories
|